Liminatus Pharma, Inc.
LIMN
$0.18
$0.00-2.17%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 26.10% | -37.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.10% | -37.29% | |||
| Operating Income | -26.10% | 37.29% | |||
| Income Before Tax | -348.00% | -1,709.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -348.00% | -1,709.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -348.00% | -1,709.36% | |||
| EBIT | -26.10% | 37.29% | |||
| EBITDA | -26.13% | 37.32% | |||
| EPS Basic | -346.52% | -1,477.55% | |||
| Normalized Basic EPS | 57.97% | -61.88% | |||
| EPS Diluted | -346.52% | -1,477.55% | |||
| Normalized Diluted EPS | 57.97% | -61.88% | |||
| Average Basic Shares Outstanding | 0.35% | 15.91% | |||
| Average Diluted Shares Outstanding | 0.35% | 15.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||